Core Viewpoint - The announcement from 加科思-B indicates a strategic partnership and investment that could enhance its position in the cardiovascular drug development sector [1] Group 1: Investment and Financial Details - 加科思-B's subsidiary, 北京加科思, and 加科瑞康 have signed an investment agreement with a partner, involving a cash payment of RMB 125 million as an initial payment and RMB 75 million as a milestone payment for acquiring 80% of 加科瑞康 [1] - Following the completion of the transaction, 北京加科思 will hold 10% of 加科瑞康, 海松资本 will own 80%, and the industry partner will have 10% [1] Group 2: Business Focus - 加科瑞康 specializes in the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research and development projects [1]

Major Events - Meili Tianyuan Medical Health (02373) acquires 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan, aiming to capture the high-end beauty market in major cities [1] - Jinhai Medical Technology (02225) is actively preparing to participate in the 8th China International Import Expo [1] - China Biopharmaceutical (01177) has its selective MEK1/2 inhibitor TQ-B3234 included in the breakthrough therapy designation program [1] - Beijing Jiakesi plans to sell 90% of Jiakexi Health through capital increase and equity transfer agreements [1] - Green Power Environmental (01330) intends to invest in establishing a joint venture in Hong Kong to expand overseas environmental business [1] - Zhonghui Biotechnology (02627) applies for full circulation of H-shares [1] Operating Performance - Legend Holdings (03396) reports that its subsidiary, Legend New Science (003022.SZ), achieved a net profit attributable to shareholders of 232 million yuan in the first three quarters, an increase of 30.32% [1] - Mongol Mining (00975) reports total raw coal production of 3.6043 million tons from UHG and BN mines in the third quarter [1] - China Resources Power (00836) reports cumulative electricity sales of 161 million megawatt-hours from its subsidiary power plants in the first nine months, a year-on-year increase of 4.2% [1] - China Coal Energy (01898) reports coal sales of 19.66 million tons in September, a year-on-year decrease of 20.1% [1] - Air China (00753) reports a 1.2% year-on-year increase in passenger capacity input and a 5.6% year-on-year increase in passenger turnover in September [1]

Group 1 - The core point of the news is that 加科思-B (01167.HK) has entered into a capital increase agreement and a share transfer agreement with a strategic partner, involving a total payment of RMB 2 billion for acquiring 80% of 加科瑞康 [1][2] - 海松资本 will pay RMB 1.25 billion as an initial payment and RMB 750 million as a milestone payment for the acquisition [1] - After the transaction, 加科思 will own 10% of 加科瑞康, 海松资本 will own 80%, and the strategic partner will hold 10% [1] Group 2 - 加科瑞康 is focused on the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research projects [1] - The transaction aligns with the company's strategic focus on developing innovative oncology products and solutions, optimizing capital allocation, and enhancing organizational efficiency [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects [2]

Group 1 - The company announced a capital increase agreement and a share transfer agreement with an industry partner, involving a total payment of RMB 2 billion for acquiring 80% of the shares in a subsidiary focused on cardiovascular drug development [1][2] - After the completion of the transaction, the ownership structure will be: Beijing Jakesi will hold 10%, Haisong Capital will hold 80%, and the industry partner will hold 10% of the shares in the subsidiary [1] - The subsidiary, Jakesi Ruikang, is primarily engaged in the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research and development projects [1] Group 2 - The company is focused on developing innovative oncology products and solutions to improve health outcomes, aligning with its strategic development in key cancer pipeline products [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects [2] - The transaction aims to optimize capital allocation and enhance organizational efficiency while maintaining future value through a risk-sharing model [2]

Group 1 - The company, 加科思-B, has signed a capital increase agreement and a share transfer agreement with an industry partner, involving a total payment of RMB 2 billion for acquiring 80% of 加科瑞康 [1][2] - After the completion of the transaction, 加科思 will own 10% of 加科瑞康, 海松资本 will own 80%, and the industry partner will hold 10% [1] - 加科瑞康 focuses on the internal research and development of cardiovascular disease treatment drugs and holds relevant intellectual property for early-stage cardiovascular research and development projects [1] Group 2 - The company is committed to developing innovative oncology products and solutions to improve health outcomes [2] - The transaction aligns with the company's strategic focus on key oncology pipeline products targeting various critical cellular pathways, optimizing capital allocation, and enhancing organizational efficiency [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 訂立增資協議及股權轉讓協議 本公司致力於開發及提供新的創新腫瘤產品及解決方案，以改善人們的健康狀況。加科 瑞康為本集團一個早期心血管研究與開發項目的項目公司。該交易符合本集團聚焦不同 關鍵細胞通路的腫瘤方向關鍵管線產品（包括KRAS、MYC、P53及腫瘤免疫等）的戰略發 展，優化資本配置，全力保障腫瘤治療核心管線的開發，實現戰略聚焦，提升組織效率， 同時以風險共擔模式保留專案未來價值。股權轉讓對價（扣除各項稅款及費用後）擬用於 本公司的Pan-KRAS抑制劑以及其他創新腫瘤項目的研發、生產及商業化。 考慮到上述因素，本公司董事（「董事」）（包括獨立非執行董事）認為增資協議及股權轉讓 協 ...

Core Viewpoint - The recent stock transfer of 加科思-B (01167) and its financial performance for the mid-2025 period indicate a significant shift in shareholder structure and a notable improvement in revenue, despite ongoing losses [1] Group 1: Stock Transfer - On October 14, 加科思-B's shares were transferred from HSBC to CITIC Securities, with a market value of HKD 314 million, representing 5.04% of the total shares [1] Group 2: Financial Performance - For the mid-2025 period, 加科思 reported revenue of RMB 45.664 million, compared to zero revenue in the same period last year [1] - The company's attributable loss narrowed to RMB 58.994 million, a 65.1% improvement year-on-year [1] - The revenue growth is primarily attributed to milestone payments from the艾力斯 licensing agreement [1]

加科思发布2025年中期业绩，该集团期内取得4566.4万元人民币，去年同期为零收入;公司拥有人应占 亏损5899.4万元，同比收窄65.1%。公告称，收入增长主要得益于艾力斯许可协议的里程碑付款。 智通财经APP获悉，香港联交所最新资料显示，10月14日，加科思-B(01167)股东将股票由香港上海汇丰 银行转入中信里昂证券，转仓市值3.14亿港元，占比5.04%。 ...

Core Insights - The recent transfer of shares for 加科思-B (01167) from 中信里昂证券 to 香港上海汇丰银行 amounts to a market value of HKD 390 million, representing 5.10% of the total shares [1] - 加科思-B's board has been informed by its concerted action members that they have collectively purchased 11,058,650 shares at a total cost of approximately HKD 96.34 million since July 16, 2025, reflecting strong confidence in the company's future prospects [1] - As of the announcement date, the concerted action members hold a total of 200 million shares, which constitutes about 25.28% of the company's issued share capital [1]

智通财经APP获悉，香港联交所最新资料显示，10月9日，加科思-B(01167)股东将股票由中信里昂证券 转入香港上海汇丰银行，转仓市值3.90亿港元，占比5.10%。 近期，加科思-B发布公告，公司董事会进一步获一致行动人士成员告知，基于对公司未来发展前景的坚 定信心，自2025年7月16日起直至本公告日期，彼等已合计买入1105.865万股公司股份，涉及总代价约 9634万港元。截至本公告日期，一致行动人士共持有公司2亿股股份，约占公司已发行股份总数的 25.28%。 ...